Michele Nanna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michele Nanna has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Laura Marcela Romero‐Acero
Cardiac Care and Vascular Medicine, Albert Einstein College of Medicine, Bronx, New York, USA
3 shared publications Giovanni J. Nanna
Zucker School of Medicine at Hofstra/Northwell, New York, USA
2 shared publicationsLaura Romero
Cardiac Care & Vascular Medicine
2 shared publications- Abdulrahman Al-Dawoudi
Faculty of Medicine and Life Sciences University of Latvia Riga Latvia
1 shared publication - Aditya Karthikeyan
Jacobi Medical Center, Albert Einstein College of Medicine, New York, USA
1 shared publication - Afthab Salam Kanniyan
Government Medical College, Kozhikode, India
1 shared publication
Latest Publications
- Open Access
- 4 July 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Ten-year trends in cardiovascular risk factors among patients hospitalised with acute myocardial infarction in Estonia: a retrospective nationwide observational study
Cardiovascular risk-factor profiles among patients hospitalised with acute myocardial infarction (AMI) can inform surveillance of a high-risk clinical cohort, but do not directly represent risk-factor prevalence in the general population. We analysed aggregate annual Estonian AMI registry data for hospitalised AMI patients during 2015-2024. AMI04 risk-factor trends were assessed using ordinary least squares regression, with sensitivity analyses for known status, age-sex standardisation to the pooled hospitalised AMI cohort, COVID-period exclusion, AMI case mix, and national hospitalised AMI burden. Documented smoking increased from 25.5% in 2015 to 28.1% in 2024 (β = 0.302% points/year; 95% CI 0.014 to 0.590; p = 0.042). The smoking trend remained significant in known-status analyses and after age-sex standardisation, although the crude observed trend became borderline after excluding 2020-2021. Documented dyslipidaemia increased descriptively, but full-period crude and age-sex-standardised trends were borderline, and unknown dyslipidaemia status decreased over time. Annual AMI attacks and national hospitalised AMI burden declined, with concurrent changes in sex and age composition. Among hospitalised AMI patients in Estonia, documented smoking increased during 2015-2024 and remained consistent in known-status and age-sex-standardised sensitivity analyses. Dyslipidaemia trends require cautious interpretation because unknown status changed over time. These aggregate registry findings describe a selected hospitalised AMI cohort and should not be interpreted as direct evidence of national prevention-policy success or failure.
- 4 July 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessTen-year trends in cardiovascular risk factors among patients hospitalised with acute myocardial infarction in Estonia: a retrospective nationwide observational study
Cardiovascular risk-factor profiles among patients hospitalised with acute myocardial infarction (AMI) can inform surveillance of a high-risk clinical cohort, but do not directly represent risk-factor prevalence in the general population. We analysed aggregate annual Estonian AMI registry data for hospitalised AMI patients during 2015-2024. AMI04 risk-factor trends were assessed using ordinary least squares regression, with sensitivity analyses for known status, age-sex standardisation to the pooled hospitalised AMI cohort, COVID-period exclusion, AMI case mix, and national hospitalised AMI burden. Documented smoking increased from 25.5% in 2015 to 28.1% in 2024 (β = 0.302% points/year; 95% CI 0.014 to 0.590; p = 0.042). The smoking trend remained significant in known-status analyses and after age-sex standardisation, although the crude observed trend became borderline after excluding 2020-2021. Documented dyslipidaemia increased descriptively, but full-period crude and age-sex-standardised trends were borderline, and unknown dyslipidaemia status decreased over time. Annual AMI attacks and national hospitalised AMI burden declined, with concurrent changes in sex and age composition. Among hospitalised AMI patients in Estonia, documented smoking increased during 2015-2024 and remained consistent in known-status and age-sex-standardised sensitivity analyses. Dyslipidaemia trends require cautious interpretation because unknown status changed over time. These aggregate registry findings describe a selected hospitalised AMI cohort and should not be interpreted as direct evidence of national prevention-policy success or failure.
- 18 December 2025
- Published by Wiley in Echocardiography
- Vol. 42 (12) , e70376
Aortic Regurgitation Grading: Reproducibility, Relevance, and the Case for Individualized Imaging
- 18 December 2025
- Published by Wiley in Echocardiography
- Vol. 42 (12) , e70376
Aortic Regurgitation Grading: Reproducibility, Relevance, and the Case for Individualized Imaging
- 9 October 2025
- Published by Wiley in Echocardiography
- Vol. 42 (10) , e70311
Integrating Strain, Myocardial Work, and Coronary Flow Into Stress Echocardiography: A Precision Framework for Ischemia Diagnosis
- 9 October 2025
- Published by Wiley in Echocardiography
- Vol. 42 (10) , e70311
Integrating Strain, Myocardial Work, and Coronary Flow Into Stress Echocardiography: A Precision Framework for Ischemia Diagnosis
- 22 September 2025
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 38 (12) , 1142-1145
Venous Excess Ultrasound in Decompensated Heart Failure: Prognostic Strength Signals Readiness for Therapeutic Evaluation
- 22 September 2025
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 38 (12) , 1142-1145
Venous Excess Ultrasound in Decompensated Heart Failure: Prognostic Strength Signals Readiness for Therapeutic Evaluation
- 16 March 2025
- Published by Wiley in Echocardiography
- Vol. 42 (3) , e70129
Defining Normal Reference Ranges of Left Ventricular Global Longitudinal Strain Among Different Vendors: Are We There Yet?
- 16 March 2025
- Published by Wiley in Echocardiography
- Vol. 42 (3) , e70129
Defining Normal Reference Ranges of Left Ventricular Global Longitudinal Strain Among Different Vendors: Are We There Yet?
- Open Access
- 3 March 2025
- Published by Wiley
DEFINING NORMAL REFERENCE RANGES OF LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN AMONG DIFFERENT VENDORS: ARE WE THERE YET?
- 3 March 2025
- Published by Wiley
Open AccessDEFINING NORMAL REFERENCE RANGES OF LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN AMONG DIFFERENT VENDORS: ARE WE THERE YET?
- Open Access
- 2 April 2024
- Published by Wiley
THE ADDED VALUE OF LEFT ATRIAL STRAIN IN CANCER-THERAPY-RELATED CARDIAC DYSFUNCTION
THE ADDED VALUE OF LEFT ATRIAL STRAIN IN CANCER-THERAPY-RELATED CARDIAC DYSFUNCTIONByLaura Romero, MD and Michele Nanna, MDAlbert Einstein Coll of Med/ Cardiac Care and Vascular Medicine, Bronx, NYCorrespondence:Michele Nanna, MD,Associate Professor of Medicine, Albert Einstein College of Medicine/ Cardiac Care and Vascular Medicine1461 Astor Ave, Bronx, NY 10469, USAEmail: mnannamd@cardiovascularcare.orgCancer-therapy-related cardiac dysfunction (CTRCD) is an undesirable side effect of chemotherapy that occurs in approximately 10% of the patients [1]. Targeting early detection and advances in treatment increases cancer survivors [2]. The American Society of Echocardiography and the European Association of Cardiovascular Imaging guidelines recommend the use of Speckle-Tracking-derived LV Global Longitudinal Strain (LV-GLS) as a more objective and accurate method to identify subclinical LV deterioration in patient undergoing chemotherapy [3].In cancer patients, assessment of Left Atrium (LA) function by Speckle Tracking has emerged as a potential tool for predicting CTRCD and its associated morbid arrhythmias such as atrial fibrillation (AF), a frequent complication in this patient population [4-6].Early research work used volumetric approaches to derive LA function parameters. Volumetric parameters are widely used in standard clinical practice and current guidelines assigns prognostic value to end-systolic LA volume in patients with suspected LV diastolic dysfunction [3]. The relationship between LV filling and volumetric parameters is not linear and reduction in LV filling pressures reduces but rarely normalizes LA volumes. LA functional parameters, as measured by novel methods of deformation analysis, more reliably detect reductions in LV filling independent of LA volumes changes [7]. Speckle tracking echocardiography–derived analysis of LA strain provides quantitative parameters for all phases of LA function (reservoir, conduit, and booster pump) and carries similar prognostic significance to that provided by volumetric approaches, in different pathological conditions including cancer patients[5,8].Knowing the impact that LA functions has in detecting CTRCD the study by Lassen and colleagues has tested LA strain in the evaluation of CTRCD as a tool for early detection of myocardial damage induced by chemotherapy [9].In this retrospective cohort study a total of 170 women with HER2+ breast cancer (stage I-IV) undergoing treatment with trastuzumab were studied at baseline, 3 months into treatment and 1 year since treatment initiation. Of note, 77 (45.3%) of participants had prior exposure to anthracycline. Also of note, during the 1- year follow-up, 23 (13.5%) patients had trastuzumab held or stopped for either a decline in Left Ventricular Ejection Fraction (LVEF) in 82.6% of cases or other non-cardiac reasons in the remaining cases.A total of 36 patients developed CTRCD during follow-up. At 3-month follow-up, CTRCD patients had lower LVEF, LV-GLS, LA reservoir strain (LA εres), and LA conduit strain rate (LAεcon-sr) compared to patients that did not develop CTRCD. In the 36 patients developing CTRCD, there was a decline in LVEF from baseline to 3-months follow-up with partial recovery at 1-year follow- up. LV-GLS also declined at 3 months, however, contrary to LVEF a recovery did not occur at 1 year follow up. In the 134 patients who did not develop CTRCD during follow-up, LA Volume Index increased from baseline to 3-month follow-up and then modestly recovered at 1-year. LA strain parameters also declined during follow-up but to a lesser degree than in the CTRCD group suggesting its value as a more sensitive parameters of subtle functional changes. This study is one of the largest studies in patients with breast cancer that has assessed changes in LA strain parameters following treatment with transtuzumab.The new information provided by Lassen et al. is in demonstrating that cancer and its treatment with Transtuzumab may negatively affect atrial function and that measurements of LA strain can detect functional changes related to cardiotoxic effects of chemotherapy. Other studies also support the fact that cancer and chemotherapy can modified LA function earlier than LV function. For example, Laufer-Perl et al. identified that cancer itself caused LA εres to be 17% lower with a further 10% relative reduction in LA εres or a decrease in LA εres below 35% in half of a population of patients undergoing chemotherapy with anthracycline. [10]. Park et al. demonstrated that while both LA εres and LV-GLS were early markers in the detection of CTRCD, LA εres reduction was more sensitive and specific than LV-GLS in predicting CTRCD [6]. Similar abnormalities in LA function were demonstrated by Tadic et al. who showed that LA reservoir and conduit function were reduced, while booster pump function was increased in cancer patients [11]. Combined with the observation by Laufer- Perl and colleagues, this raises the question as to whether LV dysfunction is only the consequence of anti- cancer therapy or if cancer itself leads to abnormalities in function. Thus, both the pathology and the therapy for that pathology can lead to LA functional impairment, which is associated with a higher risk of AF, a frequent arrhythmia in cancer patients with an impact on prognosis [4, 12].Several limitations should be noted. CTRCD is a serious complication of anticancer therapy that can beclassified into Type I exemplified by anthracyline- induced cardiac dysfunction characterized by irreversible myocardial damage due to cumulative administered dose and type II exemplified bytrastuzumab- induced cardiac dysfunction that is dose independent and reversible. The mechanism of cardiac toxicity in both types is not well defined. Current ACC/AHA guidelines recommend that patients who develop Heart Failure (HF) while receiving potentially cardiotoxic therapies should have these...
- 2 April 2024
- Published by Wiley
Open AccessTHE ADDED VALUE OF LEFT ATRIAL STRAIN IN CANCER-THERAPY-RELATED CARDIAC DYSFUNCTION
THE ADDED VALUE OF LEFT ATRIAL STRAIN IN CANCER-THERAPY-RELATED CARDIAC DYSFUNCTIONByLaura Romero, MD and Michele Nanna, MDAlbert Einstein Coll of Med/ Cardiac Care and Vascular Medicine, Bronx, NYCorrespondence:Michele Nanna, MD,Associate Professor of Medicine, Albert Einstein College of Medicine/ Cardiac Care and Vascular Medicine1461 Astor Ave, Bronx, NY 10469, USAEmail: mnannamd@cardiovascularcare.orgCancer-therapy-related cardiac dysfunction (CTRCD) is an undesirable side effect of chemotherapy that occurs in approximately 10% of the patients [1]. Targeting early detection and advances in treatment increases cancer survivors [2]. The American Society of Echocardiography and the European Association of Cardiovascular Imaging guidelines recommend the use of Speckle-Tracking-derived LV Global Longitudinal Strain (LV-GLS) as a more objective and accurate method to identify subclinical LV deterioration in patient undergoing chemotherapy [3].In cancer patients, assessment of Left Atrium (LA) function by Speckle Tracking has emerged as a potential tool for predicting CTRCD and its associated morbid arrhythmias such as atrial fibrillation (AF), a frequent complication in this patient population [4-6].Early research work used volumetric approaches to derive LA function parameters. Volumetric parameters are widely used in standard clinical practice and current guidelines assigns prognostic value to end-systolic LA volume in patients with suspected LV diastolic dysfunction [3]. The relationship between LV filling and volumetric parameters is not linear and reduction in LV filling pressures reduces but rarely normalizes LA volumes. LA functional parameters, as measured by novel methods of deformation analysis, more reliably detect reductions in LV filling independent of LA volumes changes [7]. Speckle tracking echocardiography–derived analysis of LA strain provides quantitative parameters for all phases of LA function (reservoir, conduit, and booster pump) and carries similar prognostic significance to that provided by volumetric approaches, in different pathological conditions including cancer patients[5,8].Knowing the impact that LA functions has in detecting CTRCD the study by Lassen and colleagues has tested LA strain in the evaluation of CTRCD as a tool for early detection of myocardial damage induced by chemotherapy [9].In this retrospective cohort study a total of 170 women with HER2+ breast cancer (stage I-IV) undergoing treatment with trastuzumab were studied at baseline, 3 months into treatment and 1 year since treatment initiation. Of note, 77 (45.3%) of participants had prior exposure to anthracycline. Also of note, during the 1- year follow-up, 23 (13.5%) patients had trastuzumab held or stopped for either a decline in Left Ventricular Ejection Fraction (LVEF) in 82.6% of cases or other non-cardiac reasons in the remaining cases.A total of 36 patients developed CTRCD during follow-up. At 3-month follow-up, CTRCD patients had lower LVEF, LV-GLS, LA reservoir strain (LA εres), and LA conduit strain rate (LAεcon-sr) compared to patients that did not develop CTRCD. In the 36 patients developing CTRCD, there was a decline in LVEF from baseline to 3-months follow-up with partial recovery at 1-year follow- up. LV-GLS also declined at 3 months, however, contrary to LVEF a recovery did not occur at 1 year follow up. In the 134 patients who did not develop CTRCD during follow-up, LA Volume Index increased from baseline to 3-month follow-up and then modestly recovered at 1-year. LA strain parameters also declined during follow-up but to a lesser degree than in the CTRCD group suggesting its value as a more sensitive parameters of subtle functional changes. This study is one of the largest studies in patients with breast cancer that has assessed changes in LA strain parameters following treatment with transtuzumab.The new information provided by Lassen et al. is in demonstrating that cancer and its treatment with Transtuzumab may negatively affect atrial function and that measurements of LA strain can detect functional changes related to cardiotoxic effects of chemotherapy. Other studies also support the fact that cancer and chemotherapy can modified LA function earlier than LV function. For example, Laufer-Perl et al. identified that cancer itself caused LA εres to be 17% lower with a further 10% relative reduction in LA εres or a decrease in LA εres below 35% in half of a population of patients undergoing chemotherapy with anthracycline. [10]. Park et al. demonstrated that while both LA εres and LV-GLS were early markers in the detection of CTRCD, LA εres reduction was more sensitive and specific than LV-GLS in predicting CTRCD [6]. Similar abnormalities in LA function were demonstrated by Tadic et al. who showed that LA reservoir and conduit function were reduced, while booster pump function was increased in cancer patients [11]. Combined with the observation by Laufer- Perl and colleagues, this raises the question as to whether LV dysfunction is only the consequence of anti- cancer therapy or if cancer itself leads to abnormalities in function. Thus, both the pathology and the therapy for that pathology can lead to LA functional impairment, which is associated with a higher risk of AF, a frequent arrhythmia in cancer patients with an impact on prognosis [4, 12].Several limitations should be noted. CTRCD is a serious complication of anticancer therapy that can beclassified into Type I exemplified by anthracyline- induced cardiac dysfunction characterized by irreversible myocardial damage due to cumulative administered dose and type II exemplified bytrastuzumab- induced cardiac dysfunction that is dose independent and reversible. The mechanism of cardiac toxicity in both types is not well defined. Current ACC/AHA guidelines recommend that patients who develop Heart Failure (HF) while receiving potentially cardiotoxic therapies should have these...
- 8 March 2024
- Published by Wiley in Echocardiography
- Vol. 41 (3) , e15792
The added value of left atrial strain in cancer‐therapy‐related cardiac dysfunction
- 8 March 2024
- Published by Wiley in Echocardiography
- Vol. 41 (3) , e15792
The added value of left atrial strain in cancer‐therapy‐related cardiac dysfunction